Charts for the early stopping of pilot studies
- PMID: 6726306
- DOI: 10.1200/JCO.1984.2.6.676
Charts for the early stopping of pilot studies
Abstract
Cooperative oncology groups usually run pilot studies of new agents or combinations concurrently with their major randomized clinical trials. A primary objective of these studies is to determine whether the new regimen should be tested further in a group-wide clinical trial. The accrual goals of such pilot studies are typically fixed in advance at between 30 and 40 patients, on the grounds that this number provides a reasonably tight confidence interval on the true response rate. Nevertheless early termination of pilot studies is often desirable either because the regimen appears inactive or because early results indicate extreme activity and justify immediate testing in a randomized study. Statistical charts are provided for early termination in both these situations. The charts are read by specifying the number of evaluable patients already accrued, the number of responses observed and the minimum true response rate, theta 0, at which the regimen would be considered active. The charts provide the posterior probability that the true response rate exceeds theta 0, that is, that the regimen is active. An additional chart that computes a 90% probability interval for the true response rate, based on the observed rate and sample size, is also provided. The use of the chart is illustrated with two examples from the Eastern Cooperative Oncology Group.
Similar articles
-
Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.Cancer Treat Rep. 1982 Aug;66(8):1667-8. Cancer Treat Rep. 1982. PMID: 7105058 No abstract available.
-
Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma.Cancer Treat Rep. 1986 Jul;70(7):917-8. Cancer Treat Rep. 1986. PMID: 3719586 No abstract available.
-
Phase II study of spirogermanium in the treatment of metastatic breast cancer.Cancer Treat Rep. 1984 Sep;68(9):1197-8. Cancer Treat Rep. 1984. PMID: 6478457 No abstract available.
-
Breast tumours: a review of adjuvant chemotherapy trials.Drugs Exp Clin Res. 1986;12(1-3):135-42. Drugs Exp Clin Res. 1986. PMID: 3525067 Review.
-
Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer.Semin Oncol. 1995 Jun;22(3 Suppl 6):105-8. Semin Oncol. 1995. PMID: 7597425 Review.
Cited by
-
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.NPJ Precis Oncol. 2024 Sep 9;8(1):195. doi: 10.1038/s41698-024-00698-4. NPJ Precis Oncol. 2024. PMID: 39251683 Free PMC article.
-
Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.J Biopharm Stat. 2018;28(5):824-839. doi: 10.1080/10543406.2017.1402779. Epub 2017 Nov 27. J Biopharm Stat. 2018. PMID: 29172970 Free PMC article.
-
Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.Trials. 2012 Oct 3;13:183. doi: 10.1186/1745-6215-13-183. Trials. 2012. PMID: 23034121 Free PMC article. Clinical Trial.
-
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.Breast Cancer Res Treat. 1993;25(1):57-63. doi: 10.1007/BF00662401. Breast Cancer Res Treat. 1993. PMID: 8518408 Clinical Trial.
-
A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.BMC Cancer. 2022 Mar 1;22(1):222. doi: 10.1186/s12885-022-09304-x. BMC Cancer. 2022. PMID: 35232427 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical